The efficacy of the combination of lenvatinib and pembrolizumab in the treatment of previously treated patients with advanced endometrial cancer (KEYNOTE-146 trial) has been reported.

A total of 108 patients were treated with a combination of lenvatinib 20 mg and pembrolizumab 200 mg every 3 weeks.

The response rate was 39.8%, with a median duration of response of 22.9 months. Median progression-free survival was 7.4 months and median overall survival was 17.7 months. The main adverse events were hypertension (33.3%), fatigue (8.3%), and diarrhea (7.4%). 

The researchers concluded that the results of the study showed a highly effective drug combination for the treatment of patients with advanced endometrial cancer, suggesting that the combination of lenvatinib and pembrolizumab is highly effective when standard treatment fails.